RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (“IsoRay”) (OTCBB:ISRY), a medical isotope company focusing on brachytherapy solutions for prostate and other malignant tissue cancers through use of its proprietary Cesium-131 radioisotope, announced its financial results for the first quarter of fiscal year 2007 ended September 30, 2006, and anticipated second quarter of fiscal year 2007 ending December 31, 2006. The financial results for the second quarter of fiscal year 2007 reported today should be considered preliminary until IsoRay files its Form 10-QSB for the second quarter ended December 31, 2006.
